SynAct post-hoc Phase 2b analysis backs Phase 3 path
SynAct Pharma AB says a post-hoc analysis of its Phase 2b ADVANCE study reinforces Phase 2b EXPAND results and supports Phase 3 development. FDA trial-design discussions are planned for Q4 2026.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
SynAct Pharma says advance analysis supports Phase 3 development
SynAct Pharma says advance analysis supports its Phase 3 development.